Efferon therapy

10/04/2026

Pediatric sepsis still leaves clinicians with very limited room for intervention, especially when extracorporeal therapy is considered. Our new device, , is designed to bring the benefits of Efferon multimodal hemoadsorption technology to pediatric patients.

At Efferon, we value not only technological advancement but also strong scientific evidence, and every product is supported by extensive research.

The LASSO NEO multicenter clinical trial provides strong data supporting the use of Efferon NEO in children.

will be available soon, opening a new chapter in pediatric blood purification. Thank you for being part of this journey!

09/04/2026

Every year, about 20 million children develop , and around 3,4 million children under five die. Neonatal sepsis affects 1 to 4 out of every 1,000 newborns, and too many of them don’t survive.

We believe this can and should change with the right innovations.

At Efferon, we are working on a new solution. is a multimodal pediatric device designed for the smallest and most vulnerable patients. It is manufactured in the European Union and developed in response to strong and growing demand from pediatricians.

A next-generation multimodal hemoadsorption device. The first of its kind in the world.

💥 Coming soon!

Sepsis Alliance Deutschland Erkennt Sepsis

Coming soon!

08/04/2026

Great to be part of the 23rd National Intensive Care Congress in Antalya with our partner DATEKS! With more than 1500 participants, this is one of the largest intensive care meetings, bringing together clinicians and experts from across the region.

Across multiple sessions, one idea kept coming up consistently. Endotoxin-driven inflammation needs to be addressed early, before the cascade accelerates and becomes harder to control.

This is exactly the approach behind hashtag : not to wait for deterioration, but to act early and remove the trigger.

We were also happy to see strong interest from clinicians and meaningful discussions around our technology. It is important for us to see Efferon becoming part of the clinical landscape all over the world.

A special thank you to Prof. Fethi Gül, President of the Türk Yoğun Bakım Derneği, for organizing this impactful event!

02/04/2026

Another publication on the use of in patients with septic shock, this time from Kazakhstan.

Ismailov et al. Multimodal LPS-selective hemoadsorption combined with hemodiafiltration in the intensive care of gram-negative sepsis: a multicenter observational study. General Reanimatology. 2025;21(6):4–12.

This study adds valuable data on the use of LPS-selective in combination therapy for patients with gram-negative sepsis. It’s encouraging to see Efferon becoming more accessible, and we hope this study will pave the way for further research and collaboration in this field. Importantly, this also represents a kind of geographical breakthrough, as such work has been carried out in for the first time.

Congratulations to the authors and participating centers on this achievement, and thank you for your trust and dedication!

01/04/2026

Millions of people are suffering from . But what happens after they leave the hospital?

Let's make the invisible visible and talk about post-sepsis syndrome. Raising awareness among doctors and patients is the first step toward improved long-term outcomes for survivors.
Sepsis Alliance Deutschland Erkennt Sepsis

26/03/2026

One Thing Doctors Shouldn’t Be Afraid Of in Modern Medicine

What advice would an ICU specialist Professor Ioannis Griveas give to colleagues about hemoadsorption?

According to experts in critical care, hemoadsorption is a safe and practical therapy that can help patients with sepsis and other severe conditions.

Medicine is evolving fast, and staying open to new technologies and innovative treatments can make a real difference for patients.

Follow for insights on critical care, medical innovation, and the future of healthcare.

25/03/2026

An important milestone for Efferon and our partners: our first distributors meeting, where we brought together the majority of our partners in one place.

Despite being a young company, Efferon is already present in 40 countries across four continents. And this is just the beginning! Our progress is driven by two key factors: an exceptional team and cutting-edge hashtag technology.

A key highlight of the meeting was hearing directly from our distributors. Partners shared growth stories from local markets, their participation in national congresses, and how Efferon technologies are being introduced into clinical practice. We also heard about the treatment successes in different countries. Modern ICU is can't be imagined without hemoadsorption, and we are proud that Efferon provides physicians worldwide with an effective tool to support their patients.

Looking ahead, we are actively expanding into new markets. Our ambitions are bold, and our partners are an integral part of this journey. We move forward together, hand in hand. Because success here is always mutual!

The sky is the limit, and there is much more to come. Thank you!
Palex Italia US Pharmacy Group SysteMedic Ltd - סיסטמדיק בע"מ Smart Medical Solutions

An important milestone for Efferon and our partners: our first distributors meeting, where we brought together the majority of our partners in one place.

23/03/2026

What an incredible few days at the ISICEM: International Symposium on Intensive Care and Emergency Medicine!

Great conversations, new connections, and a strong interest in , especially Efferon NEO.

Thank you to everyone who stopped by and visit us. More to come soon!

What if the next breakthrough in critical care is already happening?Efferon at ISICEM 2026: what was it like? We lifted the curtain on Efferon NEO: a new dev...

21/03/2026

As the ISICEM comes to a close, we would like to thank everyone who took the time to connect with us.

It was a pleasure to engage with so many dedicated professionals. We are encouraged by the strong interest in Efferon technologies, and in particular, the remarkable attention around .

We believe that next-generation extracorporeal therapies play a key role in . At Efferon, we are committed not only to technological innovation but also to robust scientific validation.
The effectiveness of Efferon NEO is supported by a large, multicenter clinical trial, reflecting our commitment to generating high-quality evidence.

We look forward to sharing more updates and results with you very soon.

18/03/2026

Is Hemoadsorption Worth the Cost? ICU Expert Explains

How do doctors evaluate the cost-effectiveness of hemoadsorption therapy?

According to Professor Ioannis Griveas, the answer is simple: patient outcomes. If patients recover and survival improves, the value of the therapy becomes clear.

Despite major advances in medicine, sepsis remains one of the leading causes of death worldwide, which makes effective treatments more important than ever.

Follow for insights on critical care, medical innovation, and the future of sepsis treatment.

17/03/2026

Greetings from ! The Efferon team will be in Brussels for the next few days at the International Symposium on Intensive Care and Emergency Medicine.

Join us at Stand 2.25–2.28 at the SQUARE Meeting Centre. We are excited to showcase for the first time our new device, , a pediatric solution designed to expand the benefits of Efferon blood purification technology.

We are introducing the next generation of Efferon extracorporeal blood adsorbers for the treatment of sepsis and septic shock, developed and manufactured in the European Union.

Glad to see you!

15/03/2026

In Sepsis, Waiting for Lab Results Can Be Too Late

If new studies in hemoadsorption were designed, what should they focus on?

An ICU expert explains why timing may be the most critical factor in sepsis treatment, and why relying too heavily on laboratory tests might delay life-saving decisions.

Insights from the frontline of critical care, sepsis research, and medical innovation.

Follow for more discussions on next-generation therapies and the future of medicine.